Production (Stage)
Atossa Therapeutics, Inc.
ATOS
$0.8317
-$0.0382-4.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 0.77% | 11.38% | -0.93% | -13.11% | -9.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.22% | -20.71% | -14.50% | -8.83% | -1.66% |
| Operating Income | -6.22% | 20.71% | 14.50% | 8.83% | 1.66% |
| Income Before Tax | -14.29% | 18.15% | -16.07% | 38.46% | 6.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.29% | 18.15% | -16.07% | 38.46% | 6.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.29% | 18.15% | -16.07% | 38.46% | 6.42% |
| EBIT | -6.22% | 20.71% | 14.50% | 8.83% | 1.66% |
| EBITDA | -6.24% | 20.63% | 14.52% | 8.84% | 1.69% |
| EPS Basic | -10.87% | 19.06% | -16.16% | 38.02% | 5.44% |
| Normalized Basic EPS | -10.92% | 19.12% | 11.33% | 10.95% | 5.48% |
| EPS Diluted | -10.87% | 19.06% | -16.16% | 38.02% | 5.44% |
| Normalized Diluted EPS | -10.92% | 19.12% | 11.33% | 10.95% | 5.48% |
| Average Basic Shares Outstanding | 3.07% | 1.05% | -0.02% | -0.70% | -1.03% |
| Average Diluted Shares Outstanding | 3.07% | 1.05% | -0.02% | -0.70% | -1.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |